Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
10,666,413
-
Total 13F shares
-
3,527,753
-
Share change
-
+135,934
-
Total reported value
-
$10,222,132
-
Put/Call ratio
-
876%
-
Price per share
-
$2.91
-
Number of holders
-
27
-
Value change
-
+$391,731
-
Number of buys
-
12
-
Number of sells
-
14
Institutional Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value per share (PMCB) as of Q1 2023
As of 31 Mar 2023,
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value per share (PMCB) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,527,753 shares.
The largest 10 holders included
Ayrton Capital LLC, K2 PRINCIPAL FUND, L.P., VANGUARD GROUP INC, EQUITEC PROPRIETARY MARKETS, LLC, GEODE CAPITAL MANAGEMENT, LLC, SIMPLEX TRADING, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, STATE STREET CORP, and BlackRock Inc..
This page lists
27
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.